Clinical Trial

Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomized, placebo-controlled, multi-center, double-blinded, Phase III study to determine the efficacy and safety of patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-04-13; most recent amendment 2026-04-02.
Status change: Recruiting → Active, Not Recruiting 2023-07-19
Status change: Not Yet Recruiting → Recruiting 2021-11-24
Trial Details
NCT Number NCT04848753
Lead Sponsor Shanghai Junshi Bioscience Co., Ltd.
Conditions Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Enrollment 663 participants
Start Date 2021-05-12
Primary Completion 2027-05-12 (estimated)
Study Completion 2027-05-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-08